<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04826484</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00284462</org_study_id>
    <nct_id>NCT04826484</nct_id>
  </id_info>
  <brief_title>Opioid Reduction Initiative During Outpatient Pediatric Urologic Procedures Using Exparel</brief_title>
  <acronym>Baby ORIOLES</acronym>
  <official_title>A Randomized Trial Evaluating Use of Long-Acting Liposomal Bupivacaine (Exparel®) in Reducing Narcotic Pain Requirements in Pediatric Patients Undergoing Minor Urologic Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the utility of long-acting liposomal bupivacaine (Exparel®) in&#xD;
      improving pain scores and reducing narcotic pain requirements in pediatric patients following&#xD;
      minor urologic procedures.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients who are opiate-free</measure>
    <time_frame>48 hours postoperatively</time_frame>
    <description>Percentage of patients who are opiate-free at 48 hours postoperatively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients who are opiate-free</measure>
    <time_frame>10-14 days postoperatively</time_frame>
    <description>Percentage of patients who are opiate-free at 10-14 days postoperatively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parents' postoperative pain measure (PPPM) scores</measure>
    <time_frame>48 hours postoperatively</time_frame>
    <description>15-item, yes/no behavioral checklist based on non-verbal pain cues children show following surgery. Scale is from 0 to 15, with higher scores denoting more severe pain. A score of 6+ has been validated as a threshold for a child experiencing clinically significant pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parents' postoperative pain measure (PPPM) scores</measure>
    <time_frame>10-14 days postoperatively</time_frame>
    <description>15-item, yes/no behavioral checklist based on non-verbal pain cues children show following surgery. Scale is from 0 to 15, with higher scores denoting more severe pain. A score of 6+ has been validated as a threshold for a child experiencing clinically significant pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of opioid medication used post-discharge</measure>
    <time_frame>10-14 days postoperatively</time_frame>
    <description>Amount of opioid medication (in OMEQ) used post-discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of opioid medication leftover</measure>
    <time_frame>10-14 days postoperatively</time_frame>
    <description>Amount of opioid medication (in OMEQ) leftover</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of complications</measure>
    <time_frame>10-14 days postoperatively</time_frame>
    <description>Cumulative incidence of complications related to local anesthetic systemic toxicity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Urologic Diseases</condition>
  <condition>Hypospadias</condition>
  <condition>Undescended Testes</condition>
  <condition>Chordee</condition>
  <condition>Hydrocele</condition>
  <condition>Orchiectomy</condition>
  <arm_group>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive local wound infiltration with Liposomal Bupivacaine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard 0.25% Bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive local wound infiltration with Standard 0.25% Bupivacaine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exparel 133 MG Per 10 ML Injection</intervention_name>
    <description>Local wound infiltration with Exparel 133 MG Per 10 ML Injection.</description>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine Hydrochloride</intervention_name>
    <description>Local wound infiltration with 0.25% standard bupivacaine.</description>
    <arm_group_label>Standard 0.25% Bupivacaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pediatric patients 6 years and older undergoing minor pediatric urologic surgery&#xD;
&#xD;
          -  Patients who are otherwise eligible to receive routine care following minor urologic&#xD;
             surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to receiving local anesthetics (i.e. pre-existing cardiac, renal,&#xD;
             hepatic dysfunction)&#xD;
&#xD;
          -  Pediatric patients younger than 6 years of age&#xD;
&#xD;
          -  Pediatric patients with a history of pain syndromes or are unable to tolerate opiate&#xD;
             medication&#xD;
&#xD;
          -  Unwilling to participate in 48 hours and 10-14 day follow-up phone calls&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heather N DiCarlo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew T Gabrielson, MD</last_name>
    <phone>4109550833</phone>
    <email>agabrie7@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew T Gabrielson, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>March 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypospadias</mesh_term>
    <mesh_term>Urologic Diseases</mesh_term>
    <mesh_term>Cryptorchidism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

